Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

Enhancing Alcohol Treatment Engagement in ALD Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

Who May Be Eligible (Plain English)

Who May Qualify: - Willingness to comply with all study procedures and availability for the duration of the study - Willing and able to provide willing to sign a consent form - Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals - Documented diagnosis of alcohol-related liver disease (ALD) (per protocol) - Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record. - No alcohol use treatment within the past 1 month including, but not limited to: - Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use. - Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery) - Community-based church support groups primarily focused on alcohol abstinence or reduction in use. - Residential (inpatient) alcohol treatment - Intensive outpatient programs - Any telehealth version of the above options - Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud. - Ability to speak and comprehend English Who Should NOT Join This Trial: - Unable to provide voluntary willing to sign a consent form for any reason - Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score \>=10 on the Short Blessed Test for cognitive impairment. - Unable to read or understand English - Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Willingness to comply with all study procedures and availability for the duration of the study * Willing and able to provide informed consent * Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals * Documented diagnosis of alcohol-related liver disease (ALD) (per protocol) * Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record. * No alcohol use treatment within the past 1 month including, but not limited to: * Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use. * Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery) * Community-based church support groups primarily focused on alcohol abstinence or reduction in use. * Residential (inpatient) alcohol treatment * Intensive outpatient programs * Any telehealth version of the above options * Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud. * Ability to speak and comprehend English Exclusion Criteria: * Unable to provide voluntary informed consent for any reason * Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score \>=10 on the Short Blessed Test for cognitive impairment. * Unable to read or understand English * Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation * Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine * Any other medical condition or circumstance that precludes safe and meaningful participation in the study * History of nonadherence to previous clinical or research studies

Treatments Being Tested

BEHAVIORAL

ENGAGE-ALD Application (APP)

Participants randomized to this will complete the app at the time of enrollment. If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app.

BEHAVIORAL

Treatment Facilitation bundle

Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.

BEHAVIORAL

Enhanced Usual Care

This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.

Locations (1)

Henry Ford Health
Detroit, Michigan, United States